PARP
61 articles
A New Drug Combination to Control Advanced Pancreatic Cancer
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
A Novel Combination to Slow Pancreas Tumors that Cannot Be Surgically Removed
Can a combination of standard drugs, a PARP inhibitor, and intensity modulated radiation therapy to slow pancreatic tumor growth?
A Second Opinion Makes the Difference
Irma Infante refused to give up after a stage IV pancreatic cancer diagnosis. She went for a second opinion and better treatment options.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
A Clinical Trial Matches My Genetics
Steven Merlin learned that he carried the BRCA2 mutation after he developed pancreatic cancer. He researched and found a clinical trial for BRCA carriers.
Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Challenge Grant Recipients Moving Forward
The Pancreatic Cancer Collective awarded four teams a second round of New Therapies Challenge Grants, to further develop new pancreatic cancer treatment.
The Value of Molecular Profiling and Genetic Testing
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random.
Cherishing the Simple Things
Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.
Taking Chances to Beat Pancreatic Cancer
With a family history of pancreatic cancer, Jay Bozick discovered he carries the BRCA2 mutation, which directed his treatment.
Sometimes Things Get Worse Before They Get Better
Matthew Rosenblum thought his time was limited after a pancreatic cancer diagnosis at age 32, but he’s a BRCA2 carrier, which opened treatment options.
The Butterfly Effect and Living Every Day to My Fullest
Because Helene Avraham-Katz has the BRCA2 mutation, certain chemotherapies work better and she is eligible for specific clinical trials.